Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects.

Andersson KE, Longstreth J, Brucker BM, Campeau L, Cheng L, Francis L, Fein S.

Pharm Res. 2019 Apr 29;36(6):92. doi: 10.1007/s11095-019-2628-1.

2.

Pharmacokinetics and safety profile of desmopressin oral tablet formulations in healthy Chinese subjects under fasting and fed conditions.

Li X, Zhang H, Zhu X, Li C, Chen H, Liu J, Chen G, Wu M, Liu C, Shen Z, Niu J, Liu B, Ding Y.

Int J Clin Pharmacol Ther. 2018 Sep;56(9):434-442. doi: 10.5414/CP203241.

PMID:
30049304
3.

Desmopressin acetate nasal spray for adults with nocturia.

Cohn JA, Kowalik CG, Reynolds WS, Kaufman MR, Milam DF, Dmochowski RR, Wein AJ.

Expert Rev Clin Pharmacol. 2017 Dec;10(12):1281-1293. doi: 10.1080/17512433.2017.1394185. Epub 2017 Oct 30. Review.

PMID:
29048257
4.

Evidence of partial anti-enuretic response related to poor pharmacodynamic effects of desmopressin nasal spray.

De Guchtenaere A, Raes A, Vande Walle C, Hoebeke P, Van Laecke E, Donckerwolcke R, Vande Walle J.

J Urol. 2009 Jan;181(1):302-9; discussion 309. doi: 10.1016/j.juro.2008.09.040. Epub 2008 Nov 14.

PMID:
19013601
5.
6.

Gender difference in antidiuretic response to desmopressin.

Juul KV, Klein BM, Sandström R, Erichsen L, Nørgaard JP.

Am J Physiol Renal Physiol. 2011 May;300(5):F1116-22. doi: 10.1152/ajprenal.00741.2010. Epub 2011 Mar 2.

7.

Temporal delays and individual variation in antidiuretic response to desmopressin.

Juul KV, Erichsen L, Robertson GL.

Am J Physiol Renal Physiol. 2013 Feb 1;304(3):F268-78. doi: 10.1152/ajprenal.00502.2012. Epub 2012 Nov 7.

8.

Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.

Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard JP, Djurhuus JC.

Eur J Clin Pharmacol. 2004 Aug;60(6):397-402. Epub 2004 Jun 9.

PMID:
15197520
9.

Clinical study shows improved absorption of desmopressin with novel formulation.

Fransén N, Bredenberg S, Björk E.

Pharm Res. 2009 Jul;26(7):1618-25. doi: 10.1007/s11095-009-9871-9. Epub 2009 Mar 19.

PMID:
19296208
10.

Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats.

Balducci AG, Ferraro L, Bortolotti F, Nastruzzi C, Colombo P, Sonvico F, Russo P, Colombo G.

Int J Pharm. 2013 Jan 20;440(2):154-60. doi: 10.1016/j.ijpharm.2012.09.049. Epub 2012 Oct 6.

PMID:
23046665
11.

Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.

Michelet R, Dossche L, Van Herzeele C, Van Bocxlaer J, Vermeulen A, Vande Walle J; SAFE-PEDRUG consortium.

Eur J Clin Pharmacol. 2018 Mar;74(3):297-305. doi: 10.1007/s00228-017-2386-0. Epub 2017 Dec 3.

PMID:
29198064
12.

Desmopressin duration of antidiuretic action in patients with central diabetes insipidus.

Juul KV, Bichet DG, Nørgaard JP.

Endocrine. 2011 Aug;40(1):67-74. doi: 10.1007/s12020-011-9492-z. Epub 2011 May 29.

PMID:
21626284
13.

Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials.

Kaminetsky J, Fein S, Dmochowski R, MacDiarmid S, Abrams S, Cheng M, Wein A.

J Urol. 2018 Sep;200(3):604-611. doi: 10.1016/j.juro.2018.04.050. Epub 2018 Apr 12.

PMID:
29654805
15.

Desmopressin 30 years in clinical use: a safety review.

Vande Walle J, Stockner M, Raes A, Nørgaard JP.

Curr Drug Saf. 2007 Sep;2(3):232-8. Review.

PMID:
18690973
16.

Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues.

Van de Walle J, Van Herzeele C, Raes A.

Drug Saf. 2010 Apr 1;33(4):261-71. doi: 10.2165/11319110-000000000-00000.

PMID:
20297859
17.

A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis.

Vande Walle JG, Bogaert GA, Mattsson S, Schurmans T, Hoebeke P, Deboe V, Norgaard JP; Desmopressin Oral Lyophilisate PD/PK Study Group.

BJU Int. 2006 Mar;97(3):603-9.

18.

A comparative study of pharmacodynamics and bioavailability of 2 different desmopressin nasal sprays.

Eller N, Kollenz CJ, Hitzenberger G.

Int J Clin Pharmacol Ther. 1998 Mar;36(3):139-45.

PMID:
9562229
19.

A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.

Munjal S, Gautam A, Offman E, Brand-Schieber E, Allenby K, Fisher DM.

Headache. 2016 Oct;56(9):1455-1465. doi: 10.1111/head.12905. Epub 2016 Sep 10.

PMID:
27613076

Supplemental Content

Support Center